A new schizophrenia drug, Cobenfy, showed improvement in patients with few side effects, but high dropout rates typical in such studies. Cobenfy, approved in September, works differently in the brain and includes trospium to mitigate side effects like nausea. Despite the high dropout rates, some patients experienced meaningful symptom improvement, and the drug led to weight loss. The cost of Cobenfy is significantly higher than generic alternatives, raising concerns about insurance coverage.